GeoPharma, Inc. was founded in 1985 and is headquartered in Largo, Florida. GeoPharma, Inc. is engaged in manufacturing, packaging and distributing private label dietary supplements, generic drugs, and health and beauty products under six of its companies, Innovative Health Products, Inc., Libi Labs, Belcher Pharmaceuticals, Inc., American Antibiotics, LLC and EZ-Med. Innovative Health Products and Libi Labs specialize in the development and manufacture of a range of nutritional supplements and cosmeceuticals. Its subsidiaries include Belcher Pharmaceuticals, Inc., Go2PBM Services, Inc., IHP Marketing, Inc., Breakthrough Marketing, Inc., Belcher Capital Corporation, American Antibiotics, LLC, Libi Labs, Inc., EZ-Med Company (EZ-Med) and Dynamic Health Products, Inc. Effective March 31, 2009, the Company discontinued its Distribution segment, which includes Breakthrough Engineered Nutrition.

Founded in the early 1900s, LEO Pharma has about two dozen products on the market, many of which treat psoriasis, eczema, and skin infections. The company's other focus areas include developing and manufacturing treatments for blood clot disorders, kidney disease, and support drugs for cancer treatments. Products such as Daivobet, Innohep, and Xamiol are among its best sellers. LEO Pharma has operations in Europe, as well as in the US, Middle East, Africa, and Asia. The company is wholly-owned by the Leo Foundation, which is managed by members of LEO Pharma's executive team.

The pros at ProPharma Partners offer advice to biotechnology and pharmaceutical companies on everything from corporate strategy to clinical trials. The consulting firm, which is the European arm of US-based ProPharma Partners Group, assists companies with negotiating licensing deals, corporate partnerships, and mergers and acquisitions. ProPharma also helps its clients complete FDA regulatory applications in order to register and market newly-developed drug products. The group has offices in North America, Europe, and Japan, from which it serves such clients as Cambridge Laboratories, King Pharmaceuticals, Metabolex, ReGen Therapeutics Plc, and Replidyne.

454 Life Sciences company has developed a computer-controlled instrument and related software that enable scientists to analyze whole genomes in one fell swoop, rather than a few hundred genes at a time. Parent company Roche Diagnostics distributes 454 Life Sciences' Genome Sequencing Systems to clinical laboratories, research departments of drugmakers, and other customers worldwide. Research fields include cancer and infectious disease, drug discovery, and paleontology. The company's 454 Sequencing Center provides sequencing services directly.

Fertile minds at Merck Serono help people around the world combat infertility. One of the world's top biotechs, Merck Serono focuses on recombinant genetic engineering to develop drugs. The firm also manufactures and markets therapies for neurological, dermatological, metabolic, oncology, cardiovascular, and growth disorders. It is a leader in reproductive health, with flagship drug Gonal-F at the head of its infertility product line. Other key products include beta interferon drug Rebif for the treatment of multiple sclerosis (MS) and colorectal and head/neck cancer treatment Erbitux. The company is a subsidiary of German drugmaker Merck KGaA.

Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California. Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. The Company maintains a discovery research program focused on peptide and protein therapeutics.

Cytori Therapeutics, Inc. company was founded in 1996 and is headquartered in San Diego, California. Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution System family of products, which processes patients' cells at the bedside in real time. Each member of the Celution System family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. The company also offers Celution 800/CRS System for the European cosmetic and reconstructive surgery market through a network of medical distributors; and the Celution 900/MB in Japan through its commercialization partner as part of the StemSource Cell Bank, which prepares cells for cryopreservation. Cytori Therapeutics is conducting two clinical trials on adipose-derived stem and regenerative cells processed with the Celution 600 System in patients suffering from chronic myocardial ischemia and in heart attack patients. In addition, it develops and sells thin film bioresorbable implants in Japan. Further, the company operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Additionally, it has a joint venture with Olympus Corporation to develop and manufacture second generation devices based on its Celution system.

Argenta Discovery hopes to find some help for those suffering from respiratory diseases. The pharmaceutical research and development company's quest focuses on discovering treatments for allergic asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. With seven products in various preclinical and clinical testing stages, Argenta has ongoing strategic alliances with AstraZeneca, Domantis, and Dr. Reddy's to help develop certain compounds once they clear phase II trials. Argenta also performs fee-for-service research for third-party clients which have included Genentech, Zafgen, Antisoma, and Novartis. Argenta was spun off from Aventis (now Sanofi-Aventis) in 2000.

Progenics Pharmaceuticals, Inc. company was founded in 1986 and is based in Tarrytown, New York. Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company, in collaboration with Wyeth Pharmaceuticals, provides RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation (OIC) in advanced illness patients receiving palliative care. It is also developing the HIV entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the entry co-receptor, CCR5, and is in Phase II clinical testing; and a novel HCV entry inhibitor, PRO 206. In addition, Progenics Pharmaceuticals is conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate (ADC) designed to selectively target prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as in blood vessels supplying non-prostatic solid tumors; and various Phase I clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.

ZIOPHARM Oncology, Inc. company was founded in 2003 and is based in New York, New York. ZIOPHARM Oncology, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of proprietary small molecule drug candidates that are related to cancer therapeutics. Its primary product includes Palifosfamide (Zymafos or ZIO-201), which is in phase II randomized controlled trial for the treatment of metastatic or unresectable soft tissue sarcoma as front- or second-line therapy. The company’s products in Phase I and/or II studies include Darinaparsin (Zinapar or ZIO-101), a novel anti-mitochondrial agent for the treatment of acute promyelocytic leukemia and for various other cancers; and Indibulin (Zybulin or ZIO-301), a novel small molecular-weight tubulin polymerization inhibitor. It has collaboration agreement with Harmon Hill, LLC to provide consulting and other services related to the company's development and commercialization of oncology therapeutics.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.